newsfilter
← Latest News
GlobeNewswire·

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if continuedComprehensive analysis and evaluation of available open-label extension data will followNo safety concerns